Excipient changes

These percentages are based on the assumption that the drug substance in the finished product is formulated to 100% of labeled potency. The total additive effect of all excipient changes should not change by more than 10%. 

Any qualitative and quantitative excipient changes to a narrow therapeutic drug beyond the ranges specified in the level 1 table. 

Case dissolution as for excipient change (level ) Stability No biostudy... 

Sam T. Regulatory implications of excipient changes in medicinal products. Drug Info J 2000 34 875-894. 

The total additive effect of all release controlling excipient changes should not be... 

Deletion or partial deletion of color, fragrance, or flavor Up to 5% change in approved amount of an excipient with the total additive effect of all excipient changes <=5%... 

Change in technical grade of a structure forming excipient Change in particle size distribution of the drug substance, if the drug is in suspension... 

Any quality/quantity excipient changes to NTD and beyond ranges in level 1 All other drugs not meeting the dissolution cases under level 2 Changes in the excipient ranges of LS/LP drugs beyond... 

The total additive effect of all excipient changes should not be more than 5%. Allowable changes in the composition should be based on the approved target composition and not on previous level 1 changes in the composition. 776... 

Prestrelski et al. [3.58] studied the pH conditions and different stabilizers to provide optimum storage stability for IL-2 by Fourier transform IR spectroscopy. Different pH conditions in the absence of excipients change the dry state conformation of... 

Nonclinical (Pharmtox, PK, PD) In the context of FOPs, the original sponsor will have demonstrated what the molecule per se does to the body however, since the formulation is likely different, nonclinical studies are useful in demonstrating a lack of adverse impact due to dosage form, route of administration, excipient changes, manufacturing contaminants, and supporting sameness of the active moiety. 

With justification, bracketing can be applied to studies with multiple strengths where the relative amounts of drug substance and excipients change in a formulation. Such justification can include a demonstration of comparable stability profiles among the different strengths of clinical or development batches. 

With justification, matrixing designs can be applied, for example, to different strengths where the relative amounts of drug substance and excipients change or where different excipients are used or to different container closure systems. Justification should generally be based on supporting data. For example, to matrix across two different... 

---